Results 21 to 30 of about 49,034 (266)

Thrombotic Thrombocytopenic Purpura After Ad6.COV2.S Vaccination

Cureus, 2022
Thrombotic thrombocytopenic purpura (TTP) is caused by the deficiency of ADAMTS13, a von Willebrand factor cleaving protease, which results in thrombotic microangiopathy.
S. Ramanan, H. Singh, P. Menon, Parth M Patel, VR Parmar, Devin Malik   +5 more
semanticscholar   +1 more source

Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2022
A 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 deficiency when she presented with an acute episode in ...
L. Asmis, A. Serra, A. Krafft, A. Licht, E. Leisinger, J. Henschkowski-Serra, M. Ganter, S. Hauptmann, M. Tinguely, J. K. Kremer Hovinga   +9 more
semanticscholar   +1 more source

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

International journal of hematology, 2021
Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA ...
S. H. Waqar, A. Khan, S. Memon
semanticscholar   +1 more source

Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019

Journal of Thrombosis and Haemostasis, 2022
Acute thrombotic thrombocytopenic purpura (TTP) is a life‐threatening emergency and plasma exchange (PEX) is the initial treatment shown to reduce acute mortality.
Tom P. Rory Phillip L. R. Andrew J. Rebecca J. Alexand Bull McCulloch Nicolson Doyle Shaw Langridge Sayar, Tom Bull, R. McCulloch, P. Nicolson, A. Doyle, R. Shaw, Alexander Langridge, Z. Sayar, D. Tucker, Michala Pettit, R. Perry, W. Thomas, C. Page, I. Whalley, T. Dutt, L. Garth, W. Lester, R. Buka, M. Subhan, Victoria Ware, R. Rayment, D. Castle, Astrid Etherington, Luke Carter‐Brzezinski, Jayne Peters, Claire Corrigan, N. Sharma, G. Benson, S. Challenor, T. Skinner, Rui Zhao, Lyndsay A. G. McLeod‐Kennedy, Kenneth Douglas, A. Knott, Sophie Smith, Julia S Wolf, Sophie Todd, V. Mcdonald, Alexandros Rampotas, Christopher Dean, G. Sangha, S. Pavord, N. Denny, S. Jaafar, David McLaughlin, Jonathan J Ross, M. Karanth, S. Beverstock, Lynn Mansonso, Samuel H Burrows, S. Tauro, A. Shenouda, B. Bailiff, Daniel Kajita, Joannes Hermans, H. Goradia, Emily Finan, Sarah Alford, K. Pickard, Brigit F. Greystoke, Tom Fail, Asmaa Abdussalam, L. Roberts, J. B. Clark, N. Heeney, Jennifer Young, J. Maddox, Swathy Srinath, Jahanzeb Khawaja, Jay Parkes, Samah Babiker, B. Hunt, S. Wheeldon, Paul Kerr, Molham Tahhan, Mark Vickers, A. Pike, Quentin M. Hill, Nadreen Mustafa, Azza Almaremi, Emily Hughes, S. McGoldrick, E. Loizou, I. James, Sara Boyce, I. Farmer, M. Thanigaikumar, K. Wickenden, R. Gooding, Kathryn C. Thornton, C. Kane, Adam Cole, Jessica C Griffin, S. Docherty, Kiri I. Dixon, J. Crowe, Mathew Sheridan, C. De Lord, A. Sud, A. Austin, Nichola Coooper, Chris Bailey, L. Attwell, Rachel Hall, B. Gray, Salena R. Chauhan, A. Lokare, Amy Gudger, C. Horgan, I. Venkatadasari, Israa Kaddam, Clare Mapplebeck, J. van Veen, M. Raj, K. De Abrew, E. Belsham, Cecilia Gyansah, S. Sadullah, B. Salhan, R. Murrin, Rhys L. Williams, A. Stewart, N. Cornish, S. Otton, Zeeshan Khan, S. Ackroyd, Lucia Y Chen, Nicholas Lafferty, Francesca Leonforte, N. Pemberton, Emanal Rawi, D. Triantafyllopoulou, Jagdish Adiyodi, Jun Yong, E. Jones, D. Davies, Rachel C Peck, R. Philip, Thomas Seddon, P. Cahalin, Catherine Prodger, David A. Dutton, A. Sternberg, Rajani Chengal, P. Polzella, M. Scully   +145 more
semanticscholar   +1 more source

ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2020
Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly.
X. L. Zheng, S. Vesely, S. Cataland, P. Coppo, B. Geldziler, A. Iorio, M. Matsumoto, R. Mustafa, M. Pai, G. Rock, L. Russell, R. Tarawneh, Julie Valdes, F. Peyvandi   +13 more
semanticscholar   +1 more source

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2020
Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its appropriate treatment.
X. L. Zheng, S. Vesely, S. Cataland, P. Coppo, B. Geldziler, A. Iorio, M. Matsumoto, R. Mustafa, M. Pai, G. Rock, L. Russell, R. Tarawneh, Julie Valdes, F. Peyvandi   +13 more
semanticscholar   +1 more source

Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors : a single-institution experience [PDF]

, 2010
Thrombotic microangiopathies are rare conditions characterized by microangiopathic hemolytic anemia, microthrombi, and multiorgan insult. The disorders, which include hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, are often acute and ...
Catlow, Jamie, Douglas, Kenneth W., Green, Rachel, Pollock, Kevin G.J., Young, David   +4 more
core   +1 more source

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood Advances, 2020
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and
L. Völker, J. Kaufeld, Wolfgang A. Miesbach, Sebastian Brähler, M. Reinhardt, Lucas Kühne, A. Mühlfeld, A. Schreiber, J. Gaedeke, M. Tölle, W. Jabs, Fedai Özcan, S. Markau, M. Girndt, F. Bauer, T. Westhoff, H. Felten, M. Hausberg, M. Brand, J. Gerth, M. Bieringer, M. Bommer, S. Zschiedrich, J. Schneider, S. Elitok, A. Gawlik, A. Gäckler, A. Kribben, V. Schwenger, U. Schoenermarck, M. Roeder, J. Radermacher, J. Bramstedt, A. Morgner, R. Herbst, Ana Harth, S. Potthoff, C. von Auer, R. Wendt, H. Christ, P. Brinkkoetter, J. Menne   +41 more
semanticscholar   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core   +1 more source

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

New England Journal of Medicine, 2019
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J. Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, Debjit Biswas, H. de Winter, R. Zeldin   +12 more
semanticscholar   +1 more source